# Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM

Study · id `cardio:ct-nct04682795` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04682795](<https://clinicaltrials.gov/study/NCT04682795>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04682795

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04682795. Randomized; no masking; primary purpose treatment. Start 2021-09-01 (anticipated); primary completion 2022-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04682795, source copy `cardio:ctgov-nct04682795-2021-09-01`, retrieved 2026-10-26)
- Planned start: 2021-09-01 (anticipated) (ClinicalTrials.gov record NCT04682795, source copy `cardio:ctgov-nct04682795-2021-09-01`, retrieved 2026-10-26)
- Primary completion: 2022-12-31 (anticipated) (ClinicalTrials.gov record NCT04682795, source copy `cardio:ctgov-nct04682795-2021-09-01`, retrieved 2026-10-26)
- Completion: 2022-12-31 (anticipated) (ClinicalTrials.gov record NCT04682795, source copy `cardio:ctgov-nct04682795-2021-09-01`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04682795, source copy `cardio:ctgov-nct04682795-2021-09-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04682795-2021-09-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DM
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Condition: Needle-free Injector
- Condition: Time in Range
- Intervention (Device): Needle-free injector
- Intervention (Device): Insulin pen
- Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine (`cardio:org-second-affiliated-hospital-zhejiang-university-school-of-bfd3ac`)

## Provenance

Content hash: 0f9af16ce9cb489cbdbe899a73a5fec1903243397867ae6de5b9e925e195f139
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
